Caption Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Hold |
0
| – | – | – | 551 |
|
|
2025
Q1 | – | Sell |
-62,789
| Closed | -$472K | – | 576 |
|
|
2024
Q4 | $472K | Buy |
62,789
+42,789
| +214% | +$322K | ﹤0.01% | 306 |
|
|
2024
Q3 | $152K | Buy |
+20,000
| New | +$152K | ﹤0.01% | 330 |
|
|
2024
Q2 | – | Sell |
-60,000
| Closed | -$305K | – | 441 |
|
|
2024
Q1 | $305K | Buy |
+60,000
| New | +$305K | ﹤0.01% | 251 |
|
|
2023
Q4 | – | Hold |
0
| – | – | – | 487 |
|
|
2023
Q3 | – | Hold |
0
| – | – | – | 449 |
|
|
2023
Q2 | – | Sell |
-16,300
| Closed | -$136K | – | 393 |
|
|
2023
Q1 | $136K | Sell |
16,300
-39,500
| -71% | -$329K | ﹤0.01% | 261 |
|
|
2022
Q4 | $641K | Sell |
55,800
-94,700
| -63% | -$1.09M | 0.01% | 188 |
|
|
2022
Q3 | $1.9M | Buy |
150,500
+30,500
| +25% | +$384K | 0.03% | 67 |
|
|
2022
Q2 | $1.27M | Sell |
120,000
-120,000
| -50% | -$1.27M | 0.02% | 159 |
|
|
2022
Q1 | $3.9M | Buy |
240,000
+110,500
| +85% | +$1.8M | 0.05% | 96 |
|
|
2021
Q4 | $1.79M | Sell |
129,500
-34,100
| -21% | -$472K | 0.02% | 180 |
|
|
2021
Q3 | $2.35M | Sell |
163,600
-341,400
| -68% | -$4.91M | 0.03% | 144 |
|
|
2021
Q2 | $7.98M | Buy |
+505,000
| New | +$7.98M | 0.1% | 30 |
|
|
2021
Q1 | – | Hold |
0
| – | – | – | 408 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 341 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 312 |
|
|
2019
Q3 | – | Sell |
-4,400
| Closed | -$16K | – | 284 |
|
|
2019
Q2 | $16K | Sell |
4,400
-20,600
| -82% | -$74.9K | ﹤0.01% | 228 |
|
|
2019
Q1 | $203K | Buy |
+25,000
| New | +$203K | 0.01% | 164 |
|